Magnetic Resonance Imaging in Determining Extent of Cancer in Patients With Newly Diagnosed Glioma

This study is currently recruiting patients.

Sponsored by

National Cancer Institute (NCI)

Jonsson Comprehensive Cancer Center

Purpose

RATIONALE: New imaging procedures, such as proton magnetic resonance spectroscopic imaging and diffusion magnetic resonance imaging, may improve the ability to detect the extent of newly diagnosed cancer. PURPOSE: Diagnostic study of magnetic resonance imaging in determining the extent of cancer in patients who have newly diagnosed glioma.

Study Type: Diagnostic

Official Title: Diagnostic Study of Magnetic Resonance Imaging Correlates of Tumor Cell Burden in Patients With Gliomas

Further Study Details: OBJECTIVES: I. Determine whether proton magnetic resonance spectroscopic imaging (1H-MRSI) and diffusion magnetic resonance imaging (DI) measures of glioma cell burden correlate with histopathologically measured cell counts in glioma patients who are scheduled to undergo surgical resection. II. Determine whether 1H-MRSI and DI measures of glioma cell burden are invariant over the short term (1 week) as steroid dose is increased in these patients.  PROTOCOL OUTLINE: Part I: Patients who are scheduled to have surgical resection of brain tumor undergo conventional magnetic resonance imaging (MRI), proton magnetic resonance spectroscopic imaging (1H-MRSI), and diffusion magnetic resonance imaging (DI) within 1 week before resection. Patients undergo conventional MRI within 72 hours after completion of surgical resection. Image characteristics of the resected tissue are correlated with histopathological measures. Part II: Patients who have clinical indications for increasing the dexamethasone dose are treated on part II of the study. Patients are stratified by status of steroid treatment (steroid naive vs prior steroid management). Patients undergo conventional MRI, 1H-MRSI, and DI within 2 days before and within 4-7 days after increasing the dexamethasone dose. Image characteristics on films taken before and after increasing the dexamethasone dose are compared.  PROJECTED ACCRUAL: A total of 75 patients will be accrued for part I of the study and a total 40 patients (20 per stratum) will be accrued for part II of the study within 4 years.  

Eligibility

Ages Eligible for Study:  16 Years  and above Criteria

PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Part I: Presurgical: presumptive diagnosis of intracranial glioma and scheduled to undergo first surgical resection OR stereotactic biopsy Postsurgical: Histologically proven intracranial glioma and scheduled to undergo surgical debulking Evaluable preoperative proton magnetic resonance spectroscopic imaging (1H-MRSI) and diffusion magnetic resonance imaging (DI) scans completed within 1 week prior to surgery Postoperative MRI, 1H-MRSI, and DI scans completed within 3 days after surgery Part II: Presurgical: presumptive diagnosis of intracranial glioma Postsurgical: Histologically proven intracranial glioma No surgery prior to completion of exit scans Clinical indication for increasing steroid dose Planned steroid changes must be from 0 to 16 mg/day or a twofold increase Evaluable 1H-MRSI and DI scans No prior treatment on this protocol Parts I and II: No contraindications for magnetic resonance imaging (MRI) (metallic implants, shrapnel fragments, claustrophobia, allergy to MRI contrast) --Prior/Concurrent Therapy-- Biologic therapy: Parts I and II: Not specified Chemotherapy: Parts I and II: Not specified Endocrine therapy: Part I: Not specified Part II: Steroid naive or prior steroid management allowed Radiotherapy: Parts I and II: See Disease Characteristics Surgery: Part I: See Disease Characteristics No information from more than 2 surgeries from any one patient Part II: See Disease Characteristics --Patient Characteristics-- Age: Parts I and II: Over 16 Performance status: Parts I and II: Not specified Life expectancy: Parts I and II: Not specified Hematopoietic: Parts I and II: Not specified Hepatic: Parts I and II: Not specified Renal: Parts I and II: Not specified

Location and Contact Information

California

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles,   California,   90095-1781,   United States; Recruiting

Timothy F. Cloughesy       310-794-7542   

Study chairs or principal investigators

Jeffry Alger,  Study Chair

Jonsson Comprehensive Cancer Center    

More Information

Study ID Numbers  199/14871;   UCLA-9808001; NCI-G00-1725

NLM Identifier  NCT00005082

Date study started November 3, 1998

Last Updated  April 1, 2000